A Study to Investigate the Irritation Potential on Healthy Intact Skin and Effect on Psoriatic Skin of Topical Applications of GW786034
Sponsor study identifier
interventional
10
1 country
1
Study Start
September 26, 2005
Actual (reported)Primary Completion
February 24, 2006
Actual (reported)Study Completion
February 24, 2006
Actual (reported)This study is an exploratory study to evaluate the effectiveness, safety and tolerability of three concentrations of GW786034 ointment following treatment to small areas of stable psoriatic plaques. Dosing will proceed using a microplaque approach, where small volumes of ointment will be applied under full occlusion to representative psoriatic plaques. The effectiveness of topical GW786034 treatments and controls will be explored using visual intensity assessments in addition to dermal imaging and histological surrogates of disease activity.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 24, 2006
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 26, 2005
Actual (reported)February 24, 2006
Actual (reported)February 24, 2006
Actual (reported)July 27, 2006
Actual (reported)July 31, 2006
Actual (reported)Visual assessment and clinical scoring of lesion treatment areas using modified Psoriasis Area Scoring Index (PASI) target lesion assessment scale Clinical lab tests vital signs adverse events clinical monitoring/observation
Up to 8 weeks
Laser doppler imaging,epidermal thickness by histology skin biopsies Primary pharmacokinetic endpoints AUC(0-t) and Cmax of GW786034 in plasma following repeat dosing
Up to 8 weeks
Eligible subjects will receive 0.1 percent pazopanib ointment.
Eligible subjects will receive 0.5 percent pazopanib ointment.
Eligible subjects will receive 1 percent pazopanib ointment.
Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.
Pazopanib vehicle will be given to subjects.
GSK Investigational Site
Paris, 75015, France
GSK Clinical Trials
GlaxoSmithKline
10 participants (actual enrollment reported by the registry).
First Submitted
July 27, 2006
First Posted
July 31, 2006
Study Start
September 26, 2005
Actual (reported)Primary Completion
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Eligible subjects will receive pazopanib vehicle as negative control.
Eligible subjects will receive 0.1 percent betamethasone valerate ointment as steroid positive control.
Eligible subjects will receive 0.005 percent calcipotriol ointment as vitamin D agonist positive control.
Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.
Calcipotriol ointment with 0.005 percent concentration will be given to subjects.
Contact the study team to confirm eligibility.
February 24, 2006
Actual (reported)Study Completion
February 24, 2006
Actual (reported)Last Updated
November 13, 2017
Record last verified: 2017-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: